1 August 2019 in OncoTargets and Therapy
Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1) gene has been studied for many years. However, its significance in breast cancer remains unclear. In this review we briefly summarized the physiological characteristics and regulation of PIM-1 kinase, and subsequently focused on the role of PIM-1 in tumors, especially breast cancer. Oncogene PIM-1 was found to be upregulated in breast cancer, especially in triple-negative breast cancer. Moreover, it is involved in tumorigenesis and the development of drug resistance, and linked to poor prognosis. A highly selective probe targeting PIM-1 for imaging has emerged, suggesting that PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of triple-negative breast cancer.
22 November 2022 in International Journal of Nanomedicine
Purpose: Owing to the lack of effective biomarkers, triple-negative breast cancer (TNBC) has the worst prognosis among all subtypes of breast cancer. Meanwhile, tremendous progress has been made to identify biomarkers for TNBC. However, limited number of biomarkers still restrain the specifically targeting outcomes against TNBC. Here, to solve the obstacle, we designed and synthesized a new type of biocompatible nanoparticles to amplify the targeting effects for TNBC theranostics. Methods: To identify the biomarker of TNBC, the expression of intercellular adhesion molecule-1 (ICAM1) was assessed by real-time polymerase chain reaction and western blot among all subtypes of breast cancer and normal breast epithelium. Then, vesicular nanoparticles based on poly(ethylene glycol)-poly(ϵ-caprolactone) copolymers were prepared by the double emulsion method and modified with anti-ICAM1 antibodies through click chemistry to conjugate with related antigens on TNBC cell membranes and then loaded with magnetic resonance imaging (MRI) contrast agent gadolinium and chemotherapeutic drug doxorubicin. The targeting capability, diagnostic and therapeutic efficacy of this nanoparticle were validated through cell-based and tumor model-based experiments. Results: ICAM1 was expressed significantly higher on TNBC than on other subtypes of breast cancer and normal breast epithelium in both mRNA and protein level. Theranostic nanoparticle modified with anti-ICAM1 was proved to be able to specifically target to TNBC in vitro experiments. Such theranostic nanoparticle also displayed enhanced diagnostic and therapeutic efficacy by specifically targeting capability and extending circulation time in tumor models. The biocompatibility and biosafety of this nanoparticle was also confirmed in vitro and in vivo. Conclusion: Overall, this new nanoparticle has been demonstrated with effective therapeutic outcomes against TNBC, providing a promising theranostic approach for MRI-guided therapy of TNBC.
10 February 2022 in Future Oncology
Aims: To develop a model based on breast MRI to stratify axillary lymph node metastasis (ALNM) in breast cancer. Patients & methods: A total of 134 eligible patients were used to build a predicting... Plain language summary Assessment of axillary lymph node metastasis burden before surgery in breast cancer patients is warranted for axillary management. This study tried to develop a simple model ...
30 November 2025 in Future Oncology
To develop and validate a deep learning radiomics model to predict non-sentinel lymph node (NSLN) metastases in early-stage breast cancer patients with 1-2 positive sentinel lymph node (SLN) metastases. This retrospective and prospective study encompassed 1,647 patients. Clinical, pathological information, and axillary ultrasound (AUS) findings, collected. Radiomic features of breast cancer lesions were extracted from the ultrasound images. We developed predictive models based on clinical factors alone (C model), clinical factors coupled with AUS (CA model), and clinical factors integrated with both AUS and radiomic features (CAR model). The predictive performance of each model was evaluated via the area under the curve (AUC), decision curve analysis (DCA), and calibration curve analysis. The AUC values for the C model, CA model and CAR model in the test cohort were 0.812, 0.850, and 0.994, respectively. Notably, the CAR model exhibited significantly superior predictive capability compared to both the C model and CA model. In subgroups analyses, the CAR model also achieved the optimal predictive performance. The DCA curve confirmed that the CAR model possessed significant clinical implications. The CAR model had the capability to predict NSLN metastases in early-stage breast cancer with 1-2 positive SLN metastases.